The aim of this study was to evaluate the prognostic implications of the sonographic appearance of prostate cancers.
All patients with biopsy-proven prostate cancer between January 2003 and July 2004 (and at least 5 years of follow-up) were selected retrospectively. After exclusions, 101 patients constituted our study population and were divided into isoechoic (or nonvisible) and hypoechoic (or visible) lesion. The clinical outcomes of these two groups were compared. The outcomes for the two groups were significantly different (p < 0.01). For nonvisible lesions, 37 of the 41 patients (90.2%) had no disease relapse and 2 (4.9%) had biochemical failure. For the visible lesions, 37 of the 60 (61.6%) patients were free of recurrence, 7 (11.7%) had systemic metastases and 10 (16.7%) died of complications related to prostate cancer. Our data show that patients with nonvisible prostate cancer had significantly better outcomes than patients with visible lesions during a five-year period of evaluation.
Written by:
Nakano Junqueira VC, Zogbi O, Cologna A, Dos Reis RB, Tucci S Jr, Reis LO, Westphalen AC, Muglia VF. Are you the author?
Department of Internal Medicine (Imaging Science Center), School of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil.
Reference: Ultrasound Med Biol. 2012 Oct;38(10):1689-94.
doi: 10.1016/j.ultrasmedbio.2012.06.006
PubMed Abstract
PMID: 22920545
UroToday.com Prostate Cancer Section
